ALBO News and Press, Albireo Pharma Inc. From 02/25/21

Albireo Pharma (ALBO): Q4 GAAP EPS of -$1.30 beats by $0.59.Revenue of $2.72M (-57.7% Y/Y) beats by $0.38M.Press Release For further details see: Albireo Pharma EPS beats by $0.59, beats on revenue

– NDA and MAA for odevixibat accepted, on track for anticipated H2 21 launch – – Announces odevixibat co-promotion agreement with Travere, a leading rare disease company – – ASSERT global pivotal Phase 3 trial in Alagille syndrome ini...

BOSTON, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare pediatric liver disease company developing novel bile acid modulators, today announced participation in the upcoming Cowen 41st Annual Health Care Conference March 1-4, 2021. Ron Cooper, Pre...

BOSTON, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10:00 a.m. ET on Febr...

– Company outlining large global rare cholestatic liver disease opportunity – – Advancing plans for anticipated odevixibat U.S. and EU launch, with focus on market access – – Expansion opportunity beyond PFIC and beyond odevixibat ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Albireo Pharma is developing its lead product candidate Odevixibat for multiple pediatric liver disease indications. The approval of Odevixibat for Progressive Familial Intrahepatic Cholestasis (PFIC) is expected in the second half of 2021. The company is in great financial shape ...

Under priority review, the FDA accepts Albireo Pharma's (ALBO) New Drug Application ((NDA)) for odevixibat for the treatment of pruritus in patients with progressive familial intrahepatic cholestasis ((PFIC)).The FDA has set PDUFA goal date of July 20, 2021, supporting company's previous guid...

- Company receives FDA Priority Review with PDUFA date set for July 20, 2021 - - Submission data for PFIC types 1, 2, 3, supporting once-daily use across a wide range of patients - - FDA has granted odevixibat Fast Track, Rare Pediatric Disease and Orphan Drug Designat...

BOSTON, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today joins the Alagille community in commemorating the second annual International Alagille Syndrome Awareness Day on Janua...